Abstract

Vasculogenesis and angiogenesis are key processes of placental development, which occur throughout pregnancy. Placental vasculogenesis occurs during the first trimester of pregnancy culminating in the formation of hemangioblasts from intra-villous stem cells. Placental angiogenesis occurs subsequently, forming new blood vessels from existing ones. Angiogenesis also takes place at the fetomaternal interface, allowing essential spiral arteriole remodeling to establish the fetomaternal circulation. Vasculogenesis and angiogenesis in animal models and in humans have been studied in a wide variety of in vitro, physiological and pathological conditions, with a focus on the pro- and anti-angiogenic factors that control these processes. Recent studies revealed roles for new families of proteins, including direct participants such as the prokineticin family, and regulators of these processes such as the homeobox genes. This review summarizes recent advances in understanding the molecular mechanisms of actions of these families of proteins. Over the past decade, evidence suggests increased production of placental anti-angiogenic factors, as well as angiogenic factors are associated with fetal growth restriction (FGR) and preeclampsia (PE): the most threatening pathologies of human pregnancy with systemic vascular dysfunction. This review also reports novel clinical strategies targeting members of these family of proteins to treat PE and its consequent effects on the maternal vascular system.

Highlights

  • The placenta is the key organ for a successful pregnancy

  • At the feto-maternal interface, we demonstrated that EG-Vascular endothelial growth factor (VEGF) controls extra-villi angiogenesis through the inhibition of precocious invasion of extravillous trophoblasts (EVT) into the maternal spiral arteries (Hoffmann et al, 2009)

  • In 2006, we demonstrated that endocrine gland derived-vascular endothelial growth factor (EG-VEGF) and its prokineticin receptor 1 (PROKR1) receptor were upregulated by hypoxia in the human placenta (Hoffmann et al, 2006)

Read more

Summary

INTRODUCTION

The placenta is the key organ for a successful pregnancy It acts as a semi-permeable barrier to control nutrient and gasses exchanges and regulate waste produced by developing fetus. Placental vasculogenesis is followed by two phases of angiogenesis; branching angiogenesis in immature villi where new vessels form by sprouting, and non-branching angiogenesis in the stem villi, where capillary loops form through elongation These processes increase the surface area to volume ratio (Charnock-Jones, 2002; Chaddha et al, 2004; Zou et al, 2011) and enhance diffusional exchange between the maternal and fetal circulations (Kingdom et al, 2000; Kaufmann et al, 2004).

MOLECULAR REGULATION OF ANGIOGENESIS
PROKINETICIN FAMILY IN THE CONTROL OF PLACENTAL ANGIOGENESIS
KEY REGULATORS OF PROKINETICINS FOR SUCCESSFUL PLACENTAL ANGIOGENESIS
HOMEOBOX GENES AND HOMEODOMAIN PROTEINS
HOMEOBOX GENES IN MURINE AND HUMAN PLACENTAL DEVELOPMENT
GROWTH FACTOR REGULATION OF HOMEOBOX GENES IN THE PLACENTA
Activin and Inhibin
Findings
AUTHOR CONTRIBUTIONS

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.